Back to Search Start Over

Study Findings on Pharmaceutics Reported by a Researcher at Development Department [Banked Primary Progenitor Cells for Allogeneic Intervertebral Disc (IVD) Therapy: Preclinical Qualification and Functional Optimization within a Cell Spheroid...].

Source :
Drug Week; 10/18/2024, p3264-3264, 1p
Publication Year :
2024

Abstract

A recent study conducted in Epalinges, Switzerland, explored the use of primary progenitor cells for intervertebral disc (IVD) therapy. The study aimed to preclinically qualify these cells for potential use in IVD repair and regeneration. The research found that the investigated cellular active substance was highly sustainable and yielded positive results in terms of safety and functionality. The study also established defined processes for preparing IVD spheroids using a preclinically qualified allogeneic human cell source. Overall, the study emphasized the importance of using robust product components and optimal manufacturing processes to maximize the quality of cell-based formulations. [Extracted from the article]

Details

Language :
English
ISSN :
15316440
Database :
Supplemental Index
Journal :
Drug Week
Publication Type :
Periodical
Accession number :
180201021